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Serotonin and a1 adrenergic receptor antagonism may contribute to atypical 
antipsychotic drug effects. Clozapine (2.5 mglkg) drug discrimination in C57BL16 mice 
may selectively screen atypical antipsychotic drugs. Previous data show that the atypical 
antipsychotics olanzapine, risperidone, ziprasidone but not the typical antipsychotic 
haloperidol fully substitutes for clozapine. The present study demonstrated that the 
atypical antipsychotics quetiapine, sertindole, zotepine, iloperidone, melperone fully 
substituted for clozapine but aripiprazole did not. The typical antipsychotics fluphenazine 
and perphenazine failed to fully substitute for clozapine but chlorpromazine and 
thioridazine fully substituted for clozapine. This model does not differentiate between 
atypical and typical antipsychotic drugs but it may be useful in the detection of 
antipsychotics with potent serotonin and a1 adrenergic receptor antagonist actions. 
































































































































